TRKC (L686M)

NTRK3 · Variant type: point · HGVS: p.L686M

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Repotrectinib	90.6%	9.4%	84.21
2	Ponatinib	90.0%	9.9%	78.23
3	Bosutinib	89.2%	10.8%	87.22
4	Pacritinib	88.4%	11.6%	88.64
5	Nintedanib	87.3%	12.7%	90.23
6	Entrectinib	86.9%	13.1%	93.69
7	Crizotinib	86.1%	13.9%	91.39
8	Tivozanib	82.2%	17.8%	92.42
9	Cabozantinib	81.9%	18.1%	92.73
10	Darovasertib	71.5%	28.5%	96.99
11	Pralsetinib	70.4%	29.6%	93.43
12	Defactinib	69.2%	30.8%	92.68
13	Gilteritinib	67.2%	32.8%	88.97
14	Sunitinib	55.0%	45.0%	91.73
15	Ripretinib	43.2%	56.8%	92.95
16	Fedratinib	32.1%	67.9%	96.21
17	Quizartinib	31.6%	68.4%	99.50
18	Axitinib	30.7%	69.3%	93.23
19	Alpelisib	28.8%	71.2%	97.22
20	Dabrafenib	27.3%	72.7%	94.74
21	Alectinib	26.7%	73.3%	95.49
22	Sorafenib	22.7%	77.3%	96.72
23	Fostamatinib	20.3%	79.7%	96.74
24	Tenalisib	20.0%	80.0%	97.98
25	Regorafenib	15.2%	84.8%	95.99

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Repotrectinib	90.6%	98.9%	-8.3%
Ponatinib	90.0%	96.7%	-6.6%
Bosutinib	89.2%	95.6%	-6.3%
Pacritinib	88.4%	96.7%	-8.3%
Nintedanib	87.3%	96.7%	-9.4%
Entrectinib	86.9%	98.8%	-11.9%
Crizotinib	86.1%	97.3%	-11.2%
Tivozanib	82.2%	96.1%	-13.9%
Cabozantinib	81.9%	—	—
Darovasertib	71.5%	94.5%	-23.1%
Pralsetinib	70.4%	99.4%	-29.0%
Defactinib	69.2%	91.7%	-22.4%
Gilteritinib	67.2%	99.0%	-31.8%
Sunitinib	55.0%	95.4%	-40.4%
Ripretinib	43.2%	—	—
Fedratinib	32.1%	—	—
Quizartinib	31.6%	—	—
Axitinib	30.7%	—	—
Alpelisib	28.8%	99.3%	-70.4%
Dabrafenib	27.3%	—	—
Alectinib	26.7%	94.2%	-67.5%
Sorafenib	22.7%	—	—
Fostamatinib	20.3%	—	—
Tenalisib	20.0%	98.1%	-78.1%
Regorafenib	15.2%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 18.3ms